Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Is the M&A Frenzy Short-Circuiting Pharma R&D? A Former Researcher Speaks Out

  • Broadcast in Business
Pharmaguy

Pharmaguy

Featured Host
×  

Follow This Show

If you liked this show, you should follow Pharmaguy.
h:755
s:887431
archived
Play
  • Host
A conversation with Kenneth "Eric" Milgram, Ph.D., Principal, Applied Scientific Consulting, former Director, Systems Biology Technologies at Wyeth Pharmaceuticals/Pfizer, about what happens to pharmaceutical companies when they put Wall Street expectations ahead of science-driven innovation.

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled